IDiyas

For the Inventor, By the Inventor

Basel, Switzerland

Anna Vulpetti

USPTO Granted Patents = 15 

 

 

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 47(Granted Patents)


Company Filing History:

goldMedal15 out of 3,923 
 
Novartis Ag
 patents

Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):
1. 12441733 - Substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of bruton's tyrosine kinase inhibitors (2025-10-14),
2. 11673868 - Amino pyrimidine derivatives (2023-06-13),
3. 11613543 - Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors (2023-03-28),
4. 11541056 - 3-hydroxy-N-(3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives (2023-01-03),
5. 11180460 - Amino pyrimidine derivatives (2021-11-23),
6. 10457647 - Amino pyrimidine derivatives (2019-10-29),
7. 9815819 - Complement pathway modulators and uses thereof (2017-11-14),
8. 9550755 - Complement pathway modulators and uses thereof (2017-01-24),
9. 9512084 - Amino pyrimidine derivatives (2016-12-06),
10. 9487483 - Complement pathway modulators and uses thereof (2016-11-08),
11. 9468661 - Pyrrolidine derivatives and their use as complement pathway modulators (2016-10-18),
12. 9464081 - Pyrrolidine derivatives and their use as complement pathway modulators (2016-10-11),
13. 9388199 - Pyrrolidine derivatives and their use as complement pathway modulators (2016-07-12),
14. 9233111 - Pyrrolo pyrimidine derivatives (2016-01-12),
15. 9085555 - Complement pathway modulators and uses thereof (2015-07-21),

Title: Anna Vulpetti: Innovator in Pharmaceutical Chemistry

Introduction

Anna Vulpetti is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target Bruton's tyrosine kinase. With a total of 15 patents to her name, her work has the potential to impact the treatment of various diseases.

Latest Patents

Among her latest patents, Anna has developed substituted 2,4-dioxotetrahydropyrimidines as intermediates in the synthesis of Bruton's tyrosine kinase inhibitors. This invention relates to specific compounds that may play a crucial role in treating autoimmune disorders and cancers. Additionally, she has introduced new amino pyrimidine derivatives, which are expected to interact effectively with Bruton's tyrosine kinase. These novel compounds may be beneficial in treating inflammatory diseases, allergic diseases, airway diseases such as asthma and chronic obstructive pulmonary disease (COPD), and even transplant rejection.

Career Highlights

Throughout her career, Anna has worked with notable organizations, including Novartis AG and the University of Pennsylvania. Her research and innovations have positioned her as a key figure in the pharmaceutical industry, particularly in the development of therapies for complex diseases.

Collaborations

Anna has collaborated with esteemed colleagues such as Ulrich Hommel and Edwige Liliane Jeanne Lorthiois. These partnerships have further enhanced her research capabilities and contributed to her success in the field.

Conclusion

Anna Vulpetti's innovative work in pharmaceutical chemistry continues to pave the way for new treatments and therapies. Her contributions are vital in addressing significant health challenges, and her patents reflect her dedication to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…